2004
DOI: 10.1016/j.jaci.2004.09.002
|View full text |Cite
|
Sign up to set email alerts
|

Inhalation of low-dose endotoxin favors local TH2 response and primes airway phagocytes in vivo

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

1
24
0

Year Published

2006
2006
2021
2021

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 55 publications
(25 citation statements)
references
References 23 publications
(17 reference statements)
1
24
0
Order By: Relevance
“…Intravenous challenge with endotoxin is associated with decreased HRV (associated with increased risk for cardiac events), systemic inflammation, and increases in serum triglycerides and VLDL in human volunteers and in animal models (Godin et al 1996; Goldstein et al 1995; Hardardottir et al 1995; Hudgins et al 2003; Levels et al 2003; Voss et al 2004). We and others have found that bronchial challenge with endotoxin induces systemic inflammatory effects as well, even at inhaled doses that do not cause overt airway or systemic symptoms (Alexis et al 2004; Michel et al 1992, 1997). We have also observed reduced airway cytokine and macrophage responses in healthy volunteers when they were exposed to coarse PM that had been heated to deactivate biologic agents (including denature endotoxin) versus PM that had not been heated (Alexis et al 2006).…”
Section: Discussionmentioning
confidence: 84%
See 2 more Smart Citations
“…Intravenous challenge with endotoxin is associated with decreased HRV (associated with increased risk for cardiac events), systemic inflammation, and increases in serum triglycerides and VLDL in human volunteers and in animal models (Godin et al 1996; Goldstein et al 1995; Hardardottir et al 1995; Hudgins et al 2003; Levels et al 2003; Voss et al 2004). We and others have found that bronchial challenge with endotoxin induces systemic inflammatory effects as well, even at inhaled doses that do not cause overt airway or systemic symptoms (Alexis et al 2004; Michel et al 1992, 1997). We have also observed reduced airway cytokine and macrophage responses in healthy volunteers when they were exposed to coarse PM that had been heated to deactivate biologic agents (including denature endotoxin) versus PM that had not been heated (Alexis et al 2006).…”
Section: Discussionmentioning
confidence: 84%
“…Adachi et al (2006) found that intraperitoneally administered endotoxin decreases heart rate variability measures such as rMSSD (root mean square of successive differences in normal-to-normal R-R intervals) and spectral density at low and high frequencies in a mouse model. Moreover, we and others have found that bronchial challenge with endotoxin also induces systemic inflammatory effects in asthmatics, even at inhaled doses that do not cause overt airway or systemic symptoms (Alexis et al 2004; Michel et al 1992, 1997). …”
mentioning
confidence: 72%
See 1 more Smart Citation
“…The effect of endotoxin exposure on human allergic disease is even more complex, since the levels of endotoxin vary considerably in different environmental settings. Low doses of endotoxin that are subthreshold for inducing airway neutrophilia seem to result in a Th2 skewed airway inflammatory response in humans [21]. However, a recent experimental study addressing the question how inhalation of low-dose LPS affects the immediate- and late-phase bronchial and inflammatory response in cat allergic asthmatic patients failed to detect any significant effect of exposure to LPS prior to allergen challenge [22].…”
Section: Introductionmentioning
confidence: 99%
“…Toll-like receptor 4 (TLR4) is the predominant and best-characterized cell-surface receptor specific for endotoxin that also might modulate the allergic response. 1012 Mice deficient in TLR4 and challenged with ovalbumin have increased numbers of lung dendritic cells and higher titers of IgE and airway eosinophils, all markers of atopic asthma, 13 compared with wild-type mice with normal levels of TLR4. Immune downregulation by TLR4 is mediated in part through regulatory T cells, and LPS treatment increases CD4 + CD25 + cell suppressor efficiency by 10-fold, without requiring antigen-presenting cells.…”
mentioning
confidence: 99%